April 22, 2020 – April 23, 2020
Tres Cantos, Spain
THIS EVENT HAS BEEN POSTPONED IN RESPONSE TO COVID-19. PLEASE STAY TUNED FOR AN UPDATED DATE, TIME, AND OTHER MEETING DETAILS. The field of immuno-safety is a dynamic one in which changing public health concerns, novel biomedical research advances, and innovative technological developments constantly change the landscape ...
February 11, 2020
Silver Spring, Maryland, USA
The goal of this workshop is to convene key stakeholders to discuss both current and novel methodologies in preclinical and translational safety assessment of pregnancy risk associated with immunomodulatory therapy. Through the sharing of case examples, followed by longer in-depth discussion within each session, the goal ...
September 24, 2019 – September 25, 2019
Silver Spring, Maryland, USA
The goal of this workshop is to discuss the preclinical and translational safety assessment of engineered T-cell therapies. The workshop will focus on six topics, followed by an in-depth discussion.
April 9, 2019 – April 10, 2019
San Francisco, California, USA
The field of immunotoxicology is a dynamic one in which changing public health concerns, novel biomedical research advances, and innovative technological developments constantly change the landscape and the way in which work is carried out and utilized. As this field requires combined expertise in both immunology and ...
April 4, 2018 – April 5, 2018
Munich , Germany
The field of immunotoxicology is a dynamic one in which changing public health concerns, novel biomedical research advances, and innovative technological developments constantly change the landscape and the way in which work is carried out and utilized. As this field requires combined expertise in both immunology and ...
April 18, 2017 – April 19, 2017
Gaithersburg, Maryland , USA
The field of immunotoxicology is a dynamic one in which changing public health concerns, novel biomedical research advances, and innovative technological developments constantly change the landscape and the way in which work is carried out and utilized. As this field requires combined expertise in both immunology and ...
WP_Query Object
(
[query] => Array
(
[post_type] => event
[posts_per_page] => 6
[type] =>
[area] =>
[before] => 2050-01-01
[after] =>
[tags] => ITC
[showtitle] => false
[meta_query] => Array
(
[relation] => AND
[0] => Array
(
[key] => _ilsi_date
[value] => 2050-01-01
[compare] => <=
)
[1] => Array
(
[key] => _ilsi_end_date
[value] => 2050-01-01
[compare] => <=
)
)
[paged] => 3
[tax_query] => Array
(
[0] => Array
(
[taxonomy] => post_tag
[field] => name
[terms] => ITC
)
)
[meta_key] => _ilsi_date
[orderby] => meta_value
[order] => DESC
)
[query_vars] => Array
(
[post_type] => event
[posts_per_page] => 6
[type] =>
[area] =>
[before] => 2050-01-01
[after] =>
[tags] => ITC
[showtitle] => false
[meta_query] => Array
(
[relation] => AND
[0] => Array
(
[key] => _ilsi_date
[value] => 2050-01-01
[compare] => <=
)
[1] => Array
(
[key] => _ilsi_end_date
[value] => 2050-01-01
[compare] => <=
)
)
[paged] => 3
[tax_query] => Array
(
[0] => Array
(
[taxonomy] => post_tag
[field] => name
[terms] => ITC
)
)
[meta_key] => _ilsi_date
[orderby] => meta_value
[order] => DESC
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] => 814
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[suppress_filters] =>
[ignore_sticky_posts] =>
[cache_results] =>
[update_post_term_cache] => 1
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
[0] => Array
(
[taxonomy] => post_tag
[terms] => Array
(
[0] => ITC
)
[field] => name
[operator] => IN
[include_children] => 1
)
)
[relation] => AND
[table_aliases:protected] => Array
(
[0] => wp_term_relationships
)
[queried_terms] => Array
(
[post_tag] => Array
(
[terms] => Array
(
[0] => ITC
)
[field] => name
)
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
[0] => Array
(
[key] => _ilsi_date
)
[1] => Array
(
[0] => Array
(
[key] => _ilsi_date
[value] => 2050-01-01
[compare] => <=
)
[1] => Array
(
[key] => _ilsi_end_date
[value] => 2050-01-01
[compare] => <=
)
[relation] => AND
)
[relation] => AND
)
[relation] => AND
[meta_table] => wp_postmeta
[meta_id_column] => post_id
[primary_table] => wp_posts
[primary_id_column] => ID
[table_aliases:protected] => Array
(
[0] => wp_postmeta
[1] => mt1
[2] => mt2
)
[clauses:protected] => Array
(
[wp_postmeta] => Array
(
[key] => _ilsi_date
[compare] => =
[compare_key] => =
[alias] => wp_postmeta
[cast] => CHAR
)
[mt1] => Array
(
[key] => _ilsi_date
[value] => 2050-01-01
[compare] => <=
[compare_key] => =
[alias] => mt1
[cast] => CHAR
)
[mt2] => Array
(
[key] => _ilsi_end_date
[value] => 2050-01-01
[compare] => <=
[compare_key] => =
[alias] => mt2
[cast] => CHAR
)
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] =>
SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts LEFT JOIN wp_term_relationships ON (wp_posts.ID = wp_term_relationships.object_id) INNER JOIN wp_postmeta ON ( wp_posts.ID = wp_postmeta.post_id ) INNER JOIN wp_postmeta AS mt1 ON ( wp_posts.ID = mt1.post_id ) INNER JOIN wp_postmeta AS mt2 ON ( wp_posts.ID = mt2.post_id )
WHERE 1=1 AND (
wp_term_relationships.term_taxonomy_id IN (814)
) AND (
wp_postmeta.meta_key = '_ilsi_date'
AND
(
( mt1.meta_key = '_ilsi_date' AND mt1.meta_value <= '2050-01-01' )
AND
( mt2.meta_key = '_ilsi_end_date' AND mt2.meta_value <= '2050-01-01' )
)
) AND ((wp_posts.post_type = 'event' AND (wp_posts.post_status = 'publish' OR wp_posts.post_status = 'acf-disabled')))
GROUP BY wp_posts.ID
ORDER BY wp_postmeta.meta_value DESC
LIMIT 12, 6
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 21939
[post_author] => 2
[post_date] => 2019-11-07 11:34:35
[post_date_gmt] => 2019-11-07 16:34:35
[post_content] =>
THIS EVENT HAS BEEN POSTPONED IN RESPONSE TO COVID-19. PLEASE STAY TUNED FOR UPDATED DATE, TIME, AND OTHER MEETING DETAILS.
Background
The field of immuno-safety is a dynamic one in which changing public health concerns, novel biomedical research advances, and innovative technological developments constantly change the landscape and the way in which work is carried out and utilized. As this field requires combined expertise in both immunology and toxicology, the need for continued training and interdisciplinary interactions are critical for those who work within this field. This is essential both for those with an immunology background who seek to apply this expertise to drug development and safety, as well as those who wish to enhance their current drug safety expertise with a deeper understanding of immunology.
Objectives
-Review the background science of the immune system in both normal and diseased state
-Enhance awareness of toxicities associated with modulation of the immune system
-Provide a training mechanism that incorporates the latest science into preexisting drug development methodologies
Output
Beyond the dialogue that will be generated on the latest science, this training course will provide the opportunity to apply it to a drug development setting through the following means:
-Engagement and discussion with experts in the field will enable participants to see how the science translates to applicability in drug development
-The use of specific case studies will engage and illustrate to participants how they can systematically progress on a sample task
[post_title] => Cancer Immunotherapies: Biology, Therapeutic Approaches, and Immune Related Safety Assessments
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cancer-immunotherapies-biology-therapeutic-approaches-and-immune-related-safety-assessments-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-10-28 14:59:49
[post_modified_gmt] => 2020-10-28 14:59:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://hesiglobal.org/?post_type=event&p=21939
[menu_order] => 0
[post_type] => event
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 22078
[post_author] => 2
[post_date] => 2020-01-02 13:06:03
[post_date_gmt] => 2020-01-02 18:06:03
[post_content] =>
ABOUT THE EVENT
The goal of this workshop is to convene key stakeholders to discuss both current and novel methodologies in preclinical and translational safety assessment of pregnancy risk associated with immunomodulatory therapy. Through the sharing of case examples, followed by a longer in-depth discussion within each session, the goal is to begin to address gaps in biology, current tools, and other aspects of pregnancy risk that need to be considered during drug development.
The workshop is intended to provide an interdisciplinary forum for industry, academia and regulatory scientists to discuss:
- The current state of reproductive immunology
- How adequate are the current set of tools/methodologies to address pregnancy risk under immunomodulatory therapies
- What additional tools/methods are currently being developed that could address gaps
- Global regulatory considerations across various immunomodulatory modalities
Requirements: To gain building access, you must bring acceptable and valid government issued identification (ID).
Registration: Up-to-date information and registration can be found here. Registration will close on February 5, 2020. Due to the format and structure of this workshop, attendance is restricted to in-person attendees only.
[post_title] => FDA/CDER - HESI Immunomodulators and Pregnancy Risk Assessment Workshop
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fda-cder-hesi-immunomodulators-and-pregnancy-risk-assessment-workshop
[to_ping] =>
[pinged] =>
[post_modified] => 2020-10-28 14:06:50
[post_modified_gmt] => 2020-10-28 14:06:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://hesiglobal.org/?post_type=event&p=22078
[menu_order] => 0
[post_type] => event
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 21355
[post_author] => 2
[post_date] => 2019-06-20 12:21:14
[post_date_gmt] => 2019-06-20 17:21:14
[post_content] =>
The goal of this workshop is to discuss the preclinical and translational safety assessment of engineered T cell therapies. The workshop will focus on six topics, followed by an in-depth discussion:
- Designing engineered T cells for optimal activity and safety
- Target expression and associated liability assessment
- In vivo models informing safety and activity
- Safety of viral and non-viral gene delivery systems – utility, risk of genomic injury
- Linking preclinical development with the clinical experience
- Regulatory considerations
Agenda: Please find workshop agenda here.
Accommodations: Click here to find a list of nearby hotels. Please note that participants are responsible for their own transportation to and from the US FDA site.
Requirements: To gain building access, you must bring acceptable and valid government issued identification (ID).
Registration: Onsite registration is now closed. To attend the workshop virtually, please use the webinar link located below.
Webinar: Click here to join the webinar.
[post_title] => FDA/CBER-HESI Workshop on the Safety Assessment of Engineered T-Cell Therapies
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fda-cber-hesi-workshop-on-the-safety-assessment-of-engineered-t-cell-therapies
[to_ping] =>
[pinged] =>
[post_modified] => 2020-10-28 15:00:39
[post_modified_gmt] => 2020-10-28 15:00:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://hesiglobal.org/?post_type=event&p=21355
[menu_order] => 0
[post_type] => event
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 20922
[post_author] => 13
[post_date] => 2019-02-05 11:54:03
[post_date_gmt] => 2019-02-05 16:54:03
[post_content] =>
[post_title] => Cancer Immunotherapies: Biology, Therapeutic Approaches, and Immune-Related Safety Assessments
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cancer-immunotherapies-biology-therapeutic-approaches-and-immune-related-safety-assessments
[to_ping] =>
[pinged] =>
[post_modified] => 2020-10-28 15:01:04
[post_modified_gmt] => 2020-10-28 15:01:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://hesiglobal.org/?post_type=event&p=20922
[menu_order] => 0
[post_type] => event
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 6660
[post_author] => 11
[post_date] => 2018-01-17 11:04:07
[post_date_gmt] => 2018-01-17 16:04:07
[post_content] =>
[post_title] => T-Cell Biology and Application to Immunopharmacology and Immunotoxicology Course
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => immunotox-training-course-2018
[to_ping] =>
[pinged] =>
[post_modified] => 2020-10-28 15:01:28
[post_modified_gmt] => 2020-10-28 15:01:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://hesiglobal.org/?post_type=event&p=6660
[menu_order] => 0
[post_type] => event
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 4396
[post_author] => 11
[post_date] => 2017-01-04 16:18:48
[post_date_gmt] => 2017-01-04 21:18:48
[post_content] =>
[post_title] => T-Cell Biology and Application to Immunopharmacology and Immunotoxicology Course
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => hesi-itc-training-course-spring-2017
[to_ping] =>
[pinged] =>
[post_modified] => 2020-10-28 15:01:42
[post_modified_gmt] => 2020-10-28 15:01:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://hesiglobal.org/?post_type=event&p=4396
[menu_order] => 0
[post_type] => event
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 6
[current_post] => -1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 21939
[post_author] => 2
[post_date] => 2019-11-07 11:34:35
[post_date_gmt] => 2019-11-07 16:34:35
[post_content] =>
THIS EVENT HAS BEEN POSTPONED IN RESPONSE TO COVID-19. PLEASE STAY TUNED FOR UPDATED DATE, TIME, AND OTHER MEETING DETAILS.
Background
The field of immuno-safety is a dynamic one in which changing public health concerns, novel biomedical research advances, and innovative technological developments constantly change the landscape and the way in which work is carried out and utilized. As this field requires combined expertise in both immunology and toxicology, the need for continued training and interdisciplinary interactions are critical for those who work within this field. This is essential both for those with an immunology background who seek to apply this expertise to drug development and safety, as well as those who wish to enhance their current drug safety expertise with a deeper understanding of immunology.
Objectives
-Review the background science of the immune system in both normal and diseased state
-Enhance awareness of toxicities associated with modulation of the immune system
-Provide a training mechanism that incorporates the latest science into preexisting drug development methodologies
Output
Beyond the dialogue that will be generated on the latest science, this training course will provide the opportunity to apply it to a drug development setting through the following means:
-Engagement and discussion with experts in the field will enable participants to see how the science translates to applicability in drug development
-The use of specific case studies will engage and illustrate to participants how they can systematically progress on a sample task
[post_title] => Cancer Immunotherapies: Biology, Therapeutic Approaches, and Immune Related Safety Assessments
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cancer-immunotherapies-biology-therapeutic-approaches-and-immune-related-safety-assessments-2
[to_ping] =>
[pinged] =>
[post_modified] => 2020-10-28 14:59:49
[post_modified_gmt] => 2020-10-28 14:59:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://hesiglobal.org/?post_type=event&p=21939
[menu_order] => 0
[post_type] => event
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 26
[max_num_pages] => 5
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] => 1
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] => 1
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] =>
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] => 1
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => 065b1fd9eb2677a8d71b2e15a731dda1
[query_vars_changed:WP_Query:private] => 1
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)